Centessa Pharmaceuticals plc financial data

Symbol
CNTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
3 Rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Centessa Pharmaceuticals Ltd (to 5/24/2021)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.27K % +15.5%
Debt-to-equity 37.1 % -4.48%
Return On Equity -52.1 % +3.52%
Return On Assets -38 % +2.29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 132M shares +35%
Common Stock, Shares, Outstanding 132M shares +34.9%
Entity Public Float 311M USD +28.7%
Common Stock, Value, Issued 357K USD +31.7%
Weighted Average Number of Shares Outstanding, Basic 116M shares +20.3%
Weighted Average Number of Shares Outstanding, Diluted 116M shares +20.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 49.4M USD -10.4%
Operating Income (Loss) -162M USD +9.03%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -158M USD +14.1%
Income Tax Expense (Benefit) 2.94M USD
Net Income (Loss) Attributable to Parent -161M USD -2.44%
Earnings Per Share, Basic -1.53 USD/shares +6.71%
Earnings Per Share, Diluted -1.53 USD/shares +6.71%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 395M USD +130%
Other Assets, Current 2.67M USD -6.47%
Assets, Current 568M USD +71%
Deferred Income Tax Assets, Net 27.1M USD -8.53%
Property, Plant and Equipment, Net 821K USD -25.5%
Operating Lease, Right-of-Use Asset 11.2M USD -7.3%
Other Assets, Noncurrent 2.23M USD +6.14%
Assets 610M USD +61.6%
Accounts Payable, Current 7.44M USD -31.4%
Employee-related Liabilities, Current 6.16M USD +17.6%
Accrued Liabilities, Current 19M USD -21.3%
Liabilities, Current 26.4M USD -24.5%
Operating Lease, Liability, Noncurrent 8.44M USD -6.4%
Other Liabilities, Noncurrent 29K USD
Liabilities 111M USD -6.27%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.1M USD +169%
Retained Earnings (Accumulated Deficit) -877M USD -22.5%
Stockholders' Equity Attributable to Parent 499M USD +92.4%
Liabilities and Equity 610M USD +61.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD +22.1%
Net Cash Provided by (Used in) Financing Activities 10.5M USD
Net Cash Provided by (Used in) Investing Activities 16.8M USD
Common Stock, Shares Authorized 184M shares +21%
Common Stock, Shares, Issued 132M shares +34.9%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.81M USD +92.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 395M USD +130%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.53M USD +7.89%
Deferred Tax Assets, Valuation Allowance 73.2M USD -22%
Deferred Tax Assets, Gross 106M USD +8.47%
Operating Lease, Liability 9.02M USD -5.07%
Depreciation 86K USD +132%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -160M USD -3.23%
Lessee, Operating Lease, Liability, to be Paid 14.4M USD -9.95%
Property, Plant and Equipment, Gross 1.54M USD +4.14%
Operating Lease, Liability, Current 577K USD +19.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.67M USD +2.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.63M USD +2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 434K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.41M USD -17.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.7M USD +1.98%
Deferred Tax Assets, Operating Loss Carryforwards 77.4M USD +5.94%
Unrecognized Tax Benefits 2.61M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.73M USD +2%
Operating Lease, Payments 400K USD
Additional Paid in Capital 1.37B USD +41%
Depreciation, Depletion and Amortization 240K USD +170%
Deferred Tax Assets, Net of Valuation Allowance 32.4M USD +822%
Share-based Payment Arrangement, Expense 32.6M USD +14.2%
Interest Expense 10.1M USD +24.2%